Design Therapeutics
Develops GeneTAC small molecules that tune disease-causing gene expression.
Something off on this page? Send us feedback.
Profile
Develops GeneTAC small molecules for inherited genetic diseases. Its clinical portfolio spans Friedreich ataxia, Fuchs endothelial corneal dystrophy, and myotonic dystrophy type 1, while the business relies on clinical development and external manufacturing.
Develops GeneTAC small molecules designed to dial disease-causing gene expression up or down. Its clinical portfolio includes DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, and DT-818 for myotonic dystrophy type 1.
Operates as a clinical-stage platform company, with drug candidates advancing through clinical studies rather than commercial product sales. Development depends on regulatory clearance and specialized external research and manufacturing capacity.
Does not operate cGMP manufacturing facilities and relies on third-party manufacturers and suppliers for GeneTAC materials. A formulation adjustment for DT-216 and a later FDA clinical hold on DT-216P2 demonstrate how clinical and regulatory requirements can alter program timing.
Company facts
Key statistics
Year to date +65.9% · Average volume (30d) 493.0K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| May 4, 2026 | Oppenheimer | Reiterate | Outperform | $18 | $21 | |
| Apr 29, 2026 | Piper Sandler | Target | $12 | $20 | ||
| Jan 7, 2026 | Oppenheimer | Target | $18 | |||
| Dec 3, 2025 | Craig-Hallum | Target | $15 | |||
| Dec 3, 2025 | Leerink Partners | Upgrade | Market Perform | Outperform | $14 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026Q2 FY26 | −$0.34 | −$0.32 | +7.1% | — | — | — | +4.76% |
| Apr 28, 2026Q1 FY26 | −$0.36 | −$0.29 | +19.4% | — | — | — | +23.26% |
| Mar 9, 2026Q4 FY25 | −$0.38 | −$0.27 | +28.9% | — | — | — | −3.66% |
| Nov 5, 2025Q3 FY25 | −$0.34 | −$0.30 | +11.8% | — | — | — | +4.89% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | −$152.0K | −$14.6M | $14.7M | $0 | −$151.0K | |
| Operating income | −$20.4M | −$21.6M | −$19.3M | −$18.2M | −$19.7M | −$22.2M | |
| Net income | −$17.7M | −$19.1M | −$17.0M | −$16.0M | −$17.6M | −$20.2M | |
| Diluted EPS | −$0.31 | −$0.34 | −$0.30 | −$0.27 | −$0.29 | −$0.32 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $207.4M · Total debt $2.0M · Total assets $215.1M · Shareholders' equity $201.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 62.46M · Float 32.94M · 52.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Simeon George | 6.61M | 10.70% | 13D | Mar 11, 2026 |
| Sr One Capital Management, LP | 6.53M | 10.45% | 13F | Aug 12, 2026 |
| Sirenia Capital Management LP | 5.96M | 9.50% | 13G | Aug 14, 2026 |
| Light Irrevocable Trust #1 dated April 22, 2019 | 3.83M | 6.90% | 13G | Feb 7, 2025 |
| Star Irrevocable Trust #1 dated April 22, 2019 | 3.83M | 6.90% | 13G | Feb 7, 2025 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Biogen
Approved FA therapy with established treatment access
- Larimar Therapeutics
Frataxin-replacement candidate advancing toward registration
- Dyne Therapeutics
Advanced DMPK-lowering therapy in global DM1 development
- PTC Therapeutics
FA program preparing an additional registration-supporting study
- Sarepta Therapeutics
Licensed DMPK-targeting siRNA in Phase 1/2 DM1 development
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Design Therapeutics | $15.11 | +0.07% | $943.7M | — | — | — | — |
| Biogen | $218.19 | −0.14% | $32.28B | 38.7 | 16.5 | 3.2 | +3.4% |
| Larimar Therapeutics | $4.09 | +2.25% | $416.6M | — | — | — | — |
| Dyne Therapeutics | $25.07 | −0.04% | $4.68B | — | — | — | — |
| PTC Therapeutics | $70.59 | +0.73% | $5.85B | — | 58.0 | 5.8 | +101.6% |
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| Median | 38.7 | 26.3 | 3.2 | +3.4% |